News | April 08, 2013

Tyrx Receives Approval for New AigisRx R Fully Resorbable Antibacterial Envelope from Health Canada

April 8, 2013 — Tyrx Inc. has received a license from Health Canada to market its new AigisRx R Fully Resorbable Antibacterial Envelope technology with implantable electronic devices (IEDs). The AigisRx R Antibacterial Envelope is specifically designed to stabilize IEDs while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation. Tyrx is the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections.

“Canada will be the first market in the world to gain access to our next generation AigisRx Antibacterial Envelope technology,” commented Robert White, Tyrx president and chief executive officer. “The AigisRx R technology includes all of the advantages of the original AigisRx, such as stability and infection reduction, but now with the added benefit of being fully resorbable.”

The AigisRx R Envelope is intended to hold the IED devices, such as pacemakers and implantable cardioverter defibrillators (ICDs) securely in place in order to provide a stable environment when implanted in the body. Additionally, the AigisRx R contains the antimicrobial agents rifampin and minocycline, which are released over a seven to 10 day period, in order to help provide protection from microbial colonization of the device during surgical implantation.

“Due to the continued increase in surgical site infections associated with cardiac implantable electronic devices (CIEDs), we are very pleased to have access to the AigisRx R Antibacterial Envelope. We hope that AigisRx R will serve as a key technology in addressing the significant impact that surgical site infections have on patient morbidity, mortality, and health care system costs,” stated Peter Guerra, head of electrophysiology at the Montreal Heart Institute.

Tyrx Inc. commercializes innovative, implantable combination drug+device products focused on infection control, including the AigisRx Antibacterial Envelope, designed to reduce surgical site infections associated with CIEDs. AigisRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including “superbugs” such as methicillin-resistant S. aureus (MRSA).

For more information: www.TYRX.com, www.HeartDeviceInfection.com

Related Content

CHLA/USC Team Designs Novel Micropacemaker

Model of the human heart with microprocessor located in the pericardial sac and attached to the left ventricle. Graphic courtesy of Business Wire.

News | Pacemakers | June 29, 2018
Investigators at Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) have...
Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block
News | Pacemakers | May 24, 2018
Syncope with bifascicular block may be caused by intermittent complete heart block, but competing diagnoses may coexist...
Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System Detects Atrial Contractions, Restores AV Synchrony
News | Pacemakers | May 24, 2018
New clinical study results demonstrate that an investigational algorithm, utilizing the accelerometer signal in the...
The Boston Scientific Essentio MRI-safe pacemaker.

The Boston Scientific Essentio MRI-safe pacemaker. It is common for pacemaker patients to need magnetic resonance imaging (MRI), which has not previously been possible because the magnetic fields could damage older devices. All pacemaker vendors now have FDA-cleared MRI compatible pacemakers. 

Feature | Pacemakers | February 13, 2018 | Dave Fornell
There have been several advancements in pacemaker technologies over the past few years.
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization

Mexican government reports conclude more than half of the population does not have access to social security or private insurance that covers a pacemaker implant, and 44 percent live in poverty. Recycling donated, explanted pacemakers offers a new option for these patients.

News | Pacemakers | November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers | June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
Videos | Pacemakers | May 23, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
micra leadless pacemaker
Feature | Pacemakers | May 16, 2017
May 16, 2017 - The preliminary results for the Medtronic Micra Transcatheter Pacing System (TPS) Post-Approval Regist
Videos | Pacemakers | May 16, 2017
This video, provided by Medtronic, demonstrates the implantation of Micra transcatheter pacing system (TPS).
closed loop stimulation, DDD-CLS, ACC17, SPAIN trial
Feature | Pacemakers | March 22, 2017
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing pro
Overlay Init